Bio-Rad Laboratories, Inc. BIO R3KPHARMA

Q: What is the current share price of Bio-Rad Laboratories, Inc. (BIO)?

As of 2026-09-19 21:16 PDT, Bio-Rad Laboratories, Inc. (BIO) trades at $380.12 on NYSE. Its 52-week range is $241.71 to $390.34.

Q: What is the market capitalisation of BIO?

Bio-Rad Laboratories, Inc. (BIO) has a market capitalisation of $8.25B on NYSE.

Q: What is the P/E ratio of BIO?

BIO trades at a trailing price-to-earnings (P/E) ratio of 46.30. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.41.

Q: What is the return on equity (ROE) of BIO?

BIO has a return on equity (ROE) of 3.11%. Its return on capital employed (ROCE) is 0.47%.

Q: Is BIO a good stock to buy?

This page provides a data-driven analysis of Bio-Rad Laboratories, Inc. (BIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Devices · United States

https://www.bio-rad.com

Company Profile ↓

$380.12

+32.37% 1Y

Mkt Cap$8.25B

P/E46.30

P/B1.41

52W High$390.34

52W Low$241.71

Book Value$268.30

EPS (TTM)$8.21

Company Overview

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 13.4% per year over the last five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.19.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $2.58B (+0.7% YoY); net profit $759.90M.
Trailing 12 Months Year-on-year growth — revenue -0.1%, earnings +18.7%.
5-Year Trend Long-term compounding — revenue CAGR 2.3%, profit CAGR 13.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	2.27%
1 Year:	-0.10%

Compounded Profit Growth

5 Years:	13.41%
1 Year:	18.70%

Stock Price Performance

1 Year:	+32.37%
6 Months:	+40.04%
3 Months:	+30.49%
1 Month:	+7.84%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 93% of range

$241.71 $390.34

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)62.30 · Neutral

Price Performance

1M+7.84%

3M+30.49%

6M+40.04%

1Y+32.37%

Valuation vs Sector

P/E of 46.30 is above the sector median of 24.83 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Profit CAGR of 13.4% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

46.30

Industry PE

24.83

Forward P/E

37.91

PEG Ratio

4.01

Book Value

$268.30

Price to Book

1.41

P/S

3.90

EV/EBITDA

22.48

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

2.27%

Profit 5Y

13.41%

Revenue (YoY)

-0.10%

Earnings (YoY)

18.70%

Profitability & Returns

ROCE

0.47%

ROE

3.11%

ROA

1.66%

Profit Margin

8.59%

Op Margin

11.18%

Gross Margin

52.04%

EPS (Latest Qtr)

$13.85

EPS (TTM)

$8.21

Balance Sheet & Liquidity

Debt/Equity

0.19

Quick Ratio

2.15

Current Ratio

3.14

Debt

$1.37B

Total Assets

$10.25B

Current Assets

Working Capital

Ownership

Promoter Holding

16.41%

Chg in Prom Hold

0.03%

FII / Inst Holding

91.25%

Chg in FII Hold

-0.18%

Financial Snapshot

Enterprise Value

$8.25B

Total Revenue (TTM)

$2.59B

EBITDA

$441.00M

Free Cash Flow

$283.19M

Operating Cash Flow

$492.60M

Shares Outstanding

21.70M

Gross Margin

52.04%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	BIO Bio-Rad Laboratories, Inc. R3KPHARMA	380.12	46.30	$8.25B	0.00%	0.47%	3.11%	2.27%	13.41%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	504.67M	534.14M	-	551.52M	575.91M	545.14M	-	553.98M	572.62M	560.63M	-	571.64M	536.88M	647.26M	-	726.80M	715.93M	747.05M	-	700.06M	691.10M	680.80M	-	676.84M	681.11M	632.12M	-	610.80M	638.50M	649.70M	-	585.40M	651.60M	653.00M	592.10M	651.00M
Gross Profit	280.20M	279.50M	314.40M	270.10M	273.40M	299.00M	345.20M	302.20M	301.70M	286.70M	332.60M	311.80M	307.80M	307.00M	330.40M	317.40M	293.00M	367.30M	460.10M	400.50M	401.10M	436.50M	399.90M	402.60M	395.00M	372.60M	397.10M	362.40M	362.50M	335.70M	366.30M	325.90M	355.10M	355.90M	342.00M	306.00M	345.30M	343.40M	309.40M	345.80M
Operating Income	26.90M	22.70M	-28.20M	26.21M	-1.70M	38.76M	45.90M	43.65M	43.79M	36.27M	-	56.61M	56.39M	57.46M	-	74.37M	51.74M	109.60M	-	100.86M	124.78M	156.80M	-	146.41M	122.89M	94.65M	-	61.91M	89.62M	90.95M	-	44.60M	101.50M	64.50M	-	23.70M	77.10M	65.30M	34.10M	72.60M
Net Income	16.60M	17.10M	-18.70M	12.40M	5.00M	22.10M	82.70M	656.80M	268.00M	269.30M	-828.50M	865.20M	598.80M	-258.80M	553.50M	685.90M	966.40M	1.31B	839.20M	980.00M	916.80M	3.93B	-1.57B	-3.37B	-925.10M	-162.80M	827.70M	69.00M	-1.16B	106.30M	349.70M	383.90M	-2.17B	653.20M	-715.80M	64.00M	317.80M	-341.90M	-527.10M	371.40M
Diluted EPS	0.56	0.58	-0.63	0.41	0.17	0.73	2.75	21.77	8.87	8.89	-27.73	28.74	19.86	-8.68	18.31	22.72	32.15	43.64	27.81	32.46	30.41	130.02	-52.54	-112.50	-31.05	-5.48	27.78	2.32	-39.59	3.64	12.14	13.45	-76.26	23.34	-25.57	2.29	11.67	-12.70	-19.55	13.85
R&D Expense	49.80M	49.90M	57.60M	49.45M	62.59M	62.08M	76.10M	49.43M	47.45M	49.24M	-	47.58M	50.12M	47.94M	-	49.30M	51.98M	59.55M	-	73.91M	63.39M	64.48M	-	59.53M	64.35M	66.81M	-	74.95M	65.04M	43.53M	-	66.40M	58.90M	91.00M	-	73.50M	60.50M	71.30M	62.90M	61.20M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	1.76B	1.78B	1.93B	2.07B	2.07B	2.13B	2.18B	2.02B	2.07B	2.16B	2.29B	2.31B	2.55B	2.92B	2.80B	2.67B	2.57B	2.58B
Gross Profit	962.52M	999.84M	1.09B	1.18B	1.16B	1.18B	1.18B	1.12B	1.14B	1.19B	1.22B	1.26B	1.44B	1.64B	1.57B	1.43B	1.38B	1.34B
Operating Income	182.94M	230.99M	284.01M	305.24M	264.18M	169.46M	149.98M	166.71M	55.72M	119.25M	-103.34M	229.66M	421.33M	500.34M	482.60M	337.80M	269.00M	47.20M
Net Income	89.51M	144.62M	185.49M	179.01M	165.48M	77.79M	88.84M	109.24M	26.00M	122.25M	365.61M	1.76B	3.81B	4.25B	-3.63B	-637.30M	-1.84B	759.90M
Diluted EPS	3.24	5.20	6.59	6.29	5.78	2.69	3.05	3.71	0.88	4.07	12.10	58.27	126.47	140.83	-121.79	-21.82	-65.36	27.85
R&D Expense	159.52M	163.59M	172.27M	177.60M	209.20M	210.95M	220.33M	192.97M	205.71M	250.16M	199.20M	202.71M	217.76M	260.64M	256.90M	247.40M	295.90M	275.60M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	2.54B	3.06B	3.10B	3.44B	3.39B	3.34B	3.71B	3.85B	4.27B	5.61B	8.01B	12.97B	17.80B	13.50B	12.30B	9.36B	10.58B
Total Equity	1.01B	1.07B	1.26B	1.54B	1.74B	2.02B	2.19B	2.18B	2.49B	2.58B	2.93B	4.02B	5.76B	9.89B	13.69B	9.62B	8.74B	6.57B	7.45B
Cash & Equivalents	161.76M	204.52M	649.94M	906.55M	574.23M	463.39M	331.55M	413.25M	457.55M	456.26M	383.82M	431.53M	660.67M	662.21M	470.78M	434.20M	403.80M	488.10M	529.80M
Long Term Debt	-	-	-	731.10M	731.70M	732.41M	435.62M	-	-	-	-	-	-	-	-	1.20B	1.20B	1.20B	1.20B
Total Liabilities	-	-	1.26B	1.52B	1.35B	1.43B	1.20B	1.16B	1.22B	1.27B	1.34B	1.59B	2.25B	3.09B	4.11B	3.89B	3.56B	2.79B	3.12B
Current Liabilities	-	-	419.97M	666.63M	459.12M	472.40M	487.47M	446.76M	441.35M	471.32M	502.70M	450.80M	905.50M	631.54M	680.94M	568.71M	522.80M	467.80M	517.00M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	191.37M	325.07M	225.91M	262.74M	266.48M	169.14M	273.31M	186.21M	216.07M	104.14M	285.49M	457.90M	584.97M	669.46M	194.40M	374.90M	455.20M	532.20M
Investing Cash Flow	-146.11M	-175.95M	-216.51M	-386.33M	-400.39M	919.00K	-190.51M	-166.87M	-213.88M	-175.57M	-186.98M	-208.89M	-69.89M	-797.38M	-1.21B	20.20M	-160.20M	-189.70M
Financing Cash Flow	6.33M	293.93M	228.75M	-213.56M	12.59M	-311.70M	11.69M	8.58M	9.02M	341.00K	-48.68M	-22.76M	-523.04M	-55.43M	973.60M	-425.60M	-218.80M	-283.20M
Capital Expenditure	-	-68.04M	-88.45M	-102.89M	-142.87M	-106.66M	-121.00M	-112.00M	-141.44M	-111.33M	-129.82M	-98.53M	-108.56M	-133.75M	-112.80M	-156.70M	-165.60M	-157.60M
Free Cash Flow	-	257.03M	137.46M	159.85M	123.61M	62.48M	152.31M	74.21M	74.63M	-7.20M	155.67M	359.37M	476.41M	535.72M	81.60M	218.20M	289.60M	374.60M
Share Buybacks	-	-	0	0	101.00K	0	0	0	0	2.92M	48.91M	28.00M	100.00M	50.00M	215.70M	428.70M	203.60M	295.50M

Ratios (Annual)

Figures in %.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	54.6%	56.0%	56.6%	56.9%	55.8%	55.3%	54.2%	55.5%	55.0%	55.0%	53.4%	54.4%	56.5%	56.1%	55.9%	53.4%	53.7%	51.9%
Operating Margin %	10.4%	12.9%	14.7%	14.7%	12.8%	7.9%	6.9%	8.3%	2.7%	5.5%	-4.5%	9.9%	16.6%	17.1%	17.2%	12.6%	10.5%	1.8%
Net Margin %	5.1%	8.1%	9.6%	8.6%	8.0%	3.6%	4.1%	5.4%	1.3%	5.7%	16.0%	76.1%	149.8%	145.6%	-129.5%	-23.9%	-71.9%	29.4%
ROE %	8.4%	11.5%	12.1%	10.3%	8.2%	3.6%	4.1%	4.4%	1.0%	4.2%	9.1%	30.5%	38.6%	31.1%	-37.7%	-7.3%	-28.1%	10.2%
ROCE %	-	10.9%	11.9%	11.6%	8.9%	5.8%	5.2%	5.1%	1.6%	3.2%	-2.0%	3.2%	3.4%	2.9%	3.7%	2.9%	3.0%	0.5%

Shareholding Pattern

Insiders

16.41%

Institutions

91.25%

Public Float

109.16%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	First Eagle Investment Management, LLC	12.02%	2.61M	$981.01M
2	Blackrock Inc.	7.84%	1.70M	$639.49M
3	Dimensional Fund Advisors LP	4.36%	944.55K	$355.54M
4	Vanguard Capital Management LLC	3.81%	826.97K	$311.28M
5	Vanguard Portfolio Management LLC	3.77%	816.20K	$307.23M
6	Ariel Investments, LLC	3.77%	816.75K	$307.43M
7	Earnest Partners LLC	2.68%	580.75K	$218.60M
8	State Street Corporation	2.64%	571.76K	$215.22M
9	Bank of America Corporation	2.26%	490.41K	$184.60M
10	Capital World Investors	2.13%	462.46K	$174.07M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BIO

Google News ue, 08 Sep 2026

Nuvation Bio (NUVB) Stock Looks Stretched Despite Its 354% Three Year Run - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxPbzdMR3dkMHZzREh5T1NfemIxMC1jUVFuQ1JEdkx4aHVHRXpaTDhLaVhoa0QxbjV1ZWpiSC1QOUdhbEtrYjdsTk1Ta3lOWHEzM0txQnEwNlNWMEp2Um02eEhLZ0xyNHlfZnRCSlo1cXdhbkZ1bFE0Q09XTDh4d1ZmMUp2bndZc1RJbzdvaj…

Google News Mon, 07 Sep 2026

QTTB: Q32 Bio Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiSkFVX3lxTE5kclFUOHdYekYwb3I4UWhlYTI5NnhWTHFEOTI3anFvRnlSUXVHS1ZjZzllUndLNHd0VkNobEYzZHY2bWdzSFY1U0ZR?oc=5" target="_blank">QTTB: Q32 Bio Inc. Latest Stock Price, Analysis, News and Trading I…

Google News ue, 08 Sep 2026

Alligator carries out rights issue after strategic restructuring - biostock.se

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOamw0ejk3Qkt2MkxRWXdtSVZZblhLa0twZUYzTkRwaG50R3YydGJ6RzQtRVpRMUpjR3NGZm1vam5XMm5KTE9kVHByMEtYRWEtS0x6aWZiVGZKQXAwN3BSZTRQVGtXTGhoOW5aeUFfLUZZeHp5dHpzZEJMWmwxRTVSa1VtOGpaYlVsaGNvWj…

Google News Fri, 04 Sep 2026

symbol__ Stock Quote Price and Forecast - CNN

<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1vUmM0clM3Sk1UTW9Mem9mcU1MWmFyejZEbFE2allVNlZkTjJlb2k3Z3Bncmt5Y0xyRnNlMnVwcjJRa1dFTUZuQ2Q4SzZLX2gy?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a>  <fon…

Google News ue, 08 Sep 2026

Oppenheimer raises Climb Bio stock price target on IgAN data - Investing.com

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQR3BmVlVFWGNsdzd2NHBHWl9OX25Kb1ktRzRzczlVWktlRFAtUnBxckwzM1pIYy1LZldoQTlHOWs1X2swaDR5ZE1lZUxUUk1nMFNmRjFicDlLbG9nY0xYRkxOUHk2bGxXblNWZWpOREhRaUJpWk0yMTY0cVlSak9WTHprM2VuMTNVVUhSZn…

Google News ue, 08 Sep 2026

Braveheart Bio (NASDAQ:BRVE) Trading Up 8% - Should You Buy? - marketbeat.com

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPZGxEUVVUNVkyNTRJaS1MV2piakRrRC10T0FNdHRWSU9IWXhJeS1Edmp5bi0yYW9Sa0RZQXFEOU5ZcDFhMzE2ZExlTURwWjdRNWtNSnh5QTJVVm9oQUVqUlBqTmZ3NGNndTlTTE1YUFdpSFRpdUtVT3V1RlBWRlpZeldOek9ad3RydE5GZD…

BIO — Frequently Asked Questions

What is the current share price of Bio-Rad Laboratories, Inc. (BIO)?

As of 2026-09-19 21:16 PDT, Bio-Rad Laboratories, Inc. (BIO) trades at $380.12 on NYSE. Its 52-week range is $241.71 to $390.34.

What is the market capitalisation of BIO?

Bio-Rad Laboratories, Inc. (BIO) has a market capitalisation of $8.25B on NYSE.

What is the P/E ratio of BIO?

BIO trades at a trailing price-to-earnings (P/E) ratio of 46.30. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.41.

What is the return on equity (ROE) of BIO?

BIO has a return on equity (ROE) of 3.11%. Its return on capital employed (ROCE) is 0.47%.

Is BIO a good stock to buy?

This page provides a data-driven analysis of Bio-Rad Laboratories, Inc. (BIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Bio-Rad Laboratories, Inc. BIO R3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Nuvation Bio (NUVB) Stock Looks Stretched Despite Its 354% Three Year Run - simplywall.st

QTTB: Q32 Bio Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Alligator carries out rights issue after strategic restructuring - biostock.se

symbol__ Stock Quote Price and Forecast - CNN

Oppenheimer raises Climb Bio stock price target on IgAN data - Investing.com

Braveheart Bio (NASDAQ:BRVE) Trading Up 8% - Should You Buy? - marketbeat.com

BIO — Frequently Asked Questions

What is the current share price of Bio-Rad Laboratories, Inc. (BIO)?

What is the market capitalisation of BIO?

What is the P/E ratio of BIO?

What is the return on equity (ROE) of BIO?

Is BIO a good stock to buy?

Explore More